APA (7th ed.) Citation

Walter, A., Rocconi, R. P., Monk, B. J., Herzog, T. J., Manning, L., Bognar, E., . . . Nemunaitis, J. (2021). Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecologic Oncology, 163(3), 459. https://doi.org/10.1016/j.ygyno.2021.10.004

Chicago Style (17th ed.) Citation

Walter, Adam, et al. "Gemogenovatucel-T (Vigil) Maintenance Immunotherapy: 3-year Survival Benefit in Homologous Recombination Proficient (HRP) Ovarian Cancer." Gynecologic Oncology 163, no. 3 (2021): 459. https://doi.org/10.1016/j.ygyno.2021.10.004.

MLA (9th ed.) Citation

Walter, Adam, et al. "Gemogenovatucel-T (Vigil) Maintenance Immunotherapy: 3-year Survival Benefit in Homologous Recombination Proficient (HRP) Ovarian Cancer." Gynecologic Oncology, vol. 163, no. 3, 2021, p. 459, https://doi.org/10.1016/j.ygyno.2021.10.004.